Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 2168 • 2013 ACR/ARHP Annual Meeting
Temporomandibular Joint Involvement and Quality Of Life In Juvenile Idiopathic Arthritis
Paula Frid^1,2, Ellen Nordal^3,4, Francesca Bovis⁵, Denise Marafon⁵, Donato De Angelis⁵, Sheila Oliveira⁵, Fabrizia Corona⁵, Gabrieli Simonini⁵, Joyce Davidson⁵, Helen Foster⁵, Rik Joos⁵, Ivan Foeldvari⁵, Michel Steenks⁵, Pekka Lahdenne⁵, Pavla Dolezalova⁵, Elena Palmisani⁵, Alberto Martini⁵, Angela Pistorio⁵ and Nicolino Ruperto⁵, ¹Department of Otorhinolaryngology, Division of Oral and Maxillofacial Surgery, University Hospital North Norway, Tromso, Norway, ²Public Dental Service Competence Centre of Northen Norway, Tromso, Norway, ³Department of Clinical Medicine, University of Tromsø, Tromsø, Norway, ⁴Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ⁵Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genoa, Italy
Background/Purpose: Temporomandibular joint (TMJ) arthritis in childhood is seen in a substantial percentage of children with Juvenile idiopathic arthritis (JIA) and may lead to reduced mouth…
Abstract Number: 1780 • 2013 ACR/ARHP Annual Meeting
The Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Norman T. Ilowite¹, Kristi Prather², Yuliya Lokhnygina³, Laura E. Schanberg⁴, Melissa Elder⁵, Diana Milojevic⁶, James W. Verbsky⁷, Steven J. Spalding⁸, Yukiko Kimura⁹, Lisa F. Imundo¹⁰, Marilynn G. Punaro¹¹, David D. Sherry¹², Stacey E. Tarvin¹³, Lawrence S. Zemel¹⁴, James D. Birmingham¹⁵, Beth S. Gottlieb¹⁶, Michael L. Miller¹⁷, Kathleen M. O'Neil¹⁸, Natasha M. Ruth¹⁹, Carol A. Wallace²⁰, Nora G. Singer²¹ and Christy I. Sandborg²², ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Statistics, Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Pediatrics, University of Florida, Gainesville, HI, ⁶Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁸Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, ¹¹Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹²Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹⁴Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH, ¹⁵Medicine & Pediatrics, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ¹⁶Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁷Rheumatology, Childrens Memorial Hospital, Chicago, IL, ¹⁸Division of Pediatric Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ²⁰University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²²Pediatric Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The RAndomized Placebo Phase Study Of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT) is a multicenter controlled trial using a…
Abstract Number: 790 • 2013 ACR/ARHP Annual Meeting
Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course
Carol A. Wallace¹, Edward H. Giannini², Steven J. Spalding³, Philip J. Hashkes⁴, Kathleen M. O'Neil⁵, Andrew S. Zeft⁶, Ilona S. Szer⁷, Sarah Ringold⁸, Hermine Brunner⁹, Laura E. Schanberg¹⁰, Robert P. Sundel¹¹, Diana Milojevic¹², Marilynn G. Punaro¹³, Peter Chira¹⁴, Beth S. Gottlieb¹⁵, Gloria C. Higgins¹⁶, Norman T. Ilowite¹⁷, Yukiko Kimura¹⁸, Anne Johnson⁹, Bin Huang¹⁹ and Daniel J. Lovell², ¹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁴Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, ⁵Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ⁶Pediatric Institute, Department of Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Div of Rheumatology, Rady Childrens Hosp San Diego, San Diego, CA, ⁸Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ⁹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Pediatrics, Duke University Medical Center, Durham, NC, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ¹³Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹⁴Pediatric Rheumatology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ¹⁵Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁶Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁷Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ¹⁸Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: The double-blind, randomized placebo-controlled Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT) compared the ability of 2 aggressive treatment regimens to…
Abstract Number: 280 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
Tamas Constantin¹, Ivan Foeldvari², Jelena Vojinovic³, Gerd Horneff⁴, Ruben Burgos-Vargas⁵, Irina Nikishina⁶, Jonathan Akikusa⁷, Tadej Avcin⁸, Jeffrey Chaitow⁵, Elena Koskova⁹, Bernard Lauwerys¹⁰, Jack Bukowski¹¹, Chuanbo Zang¹², Joseph Wajdula¹², Deborah Woodworth¹², Bonnie Vlahos¹³, Alberto Martini¹⁴ and Nicolino Ruperto⁵, ¹Semmelweis University, Budapest, Hungary, ²Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ³Dept Pediatric Rheumatology, Clinical Center, School of Medicine University of Nis, Nis, Serbia, ⁴Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁵PRINTO, Genoa, Italy, ⁶Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, ⁷Rheumatology, Royal Childrens Hospital, Parkville, Australia, ⁸The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, ⁹National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹⁰Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹¹Department of Specialty Care, Pfizer Inc, Collegeville, PA, ¹²Pfizer Inc., Collegeville, PA, ¹³Department of Specialty Care, Pfizer Inc., Collegeville, PA, ¹⁴Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Etanercept (ETN) is approved for the treatment of pediatric patients with the polyarticular subtype of juvenile idiopathic arthritis (JIA). In addition, based on the…
Abstract Number: 283 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison
Laura Sawyer¹, Alex Diamantopoulos², Hermine Brunner³, Fabrizio De Benedetti⁴, Nicolino Ruperto⁵, Fred Dejonckheere⁶ and Caroline Keane⁷, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³PRCSG, Cincinnati, OH, ⁴Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵PRINTO, Genoa, Italy, ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: To date there are no head-to-head trials comparing the efficacy of biologic treatments for polyarticular-course JIA (pcJIA). The purpose of this study was to…
Abstract Number: 284 • 2013 ACR/ARHP Annual Meeting
What Is the Relative Priority of the ACR Pediatric Core Set Measures for Youth With Juvenile Idiopathic Arthritis and Their Parents?
Jaime Guzman¹, Oralia Gomez-Ramirez², Susanne M. Benseler³, Roberta A. Berard⁴, Rollin Brant⁵, Ciaran M. Duffy⁶, Roman Jurencak⁷, Kiem Oen⁸, Ross E. Petty⁹, Natalie J. Shiff¹⁰ and Lori B. Tucker¹¹, ¹Pediatric Rheum/Rm K4-122, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Anthropology, University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital of Western Ontario, London, ON, Canada, ⁵Statistics, University of British Columbia, Vancouver, BC, Canada, ⁶Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Pediatric Rheumatology, BC Children's Hosptial, Vancouver, BC, Canada, ¹⁰Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ¹¹Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The ACR has endorsed a core set of six measures to assess the course of JIA and the impact of treatment: active joint count,…
Abstract Number: 290 • 2013 ACR/ARHP Annual Meeting
Children With JIA Show Distinct Patterns Of Improvement In Their Health-Related Quality Of Life During The First Year On Treatment: Growth Mixture Modeling Of a Prospective Cohort Of Newly Diagnosed Patients
Bin Huang¹, Chen Chen², Stacey Niehaus³, Hermine Brunner⁴, Rina Mina⁵ and Michael Seid⁶, ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pulmonary, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: Health-related quality of life (HRQOL) is a key outcome in clinical care and research for children with JIA. Despite excellent clinical control and the…
Abstract Number: 298 • 2013 ACR/ARHP Annual Meeting
Preliminary Prospective Study Of Ultrasonography In Patients With Juvenile Idiopathic Arthritis In Clinical Remission: Subclinical Synovitis May Predict Flare?
Vanessa B Miotto e Silva¹, Sônia A.V. Mitraud², Rita NV Furtado³, Jamil Natour³ and Maria Teresa Terreri¹, ¹Pediatrics, Escola Paulista de Medicina/ Universidade Federal de São Paulo, São Paulo, Brazil, ²Radiology and Diagnostic Imaging, Escola Paulista de Medicina/ Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, Brazil, ³Internal Medicine, Escola Paulista de Medicina/ Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood and has variable prognosis, characterized by periods of activity and remission.…
Abstract Number: 2792 • 2013 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Performance Improvement On Juvenile Idiopathic Arthritis Quality Measures
Julia G. Harris^1,2, Esi Morgan DeWitt³, Ronald M. Laxer^4,5, Stacy P. Ardoin⁶, Beth S. Gottlieb⁷, Judyann C. Olson^1,2, Murray H. Passo⁸, Jennifer E. Weiss⁹, Daniel J. Lovell¹⁰, Tzielan C. Lee¹¹, Sheetal S. Vora^12,13, Nancy Griffin¹⁴, Jason A. Stock¹⁵, Lynn M. Darbie¹⁴ and Catherine A. Bingham¹⁶, ¹Medical College of Wisconsin, Milwaukee, WI, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ⁷Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁸Pediatrics, Medical University of South Carolina, Charleston, SC, ⁹Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹²University of North Carolina Chapel Hill, Chapel Hill, NC, ¹³Levine Children's Hospital and Carolinas Medical Center, Charlotte, NC, ¹⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Pediatric Rheumatology, Penn State Hershey Children's Hospital, Hershey, PA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a multi-site learning network designed to improve outcomes of juvenile idiopathic arthritis (JIA) care. Teams…
Abstract Number: 273 • 2013 ACR/ARHP Annual Meeting
Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis
Fabrizio De Benedetti¹, Hermine Brunner², Eileen M. Baildam³, Ruben Burgos-Vargas³, Gerd Horneff³, Hans-Iko Huppertz³, Kirsten Minden⁴, Barry L. Myones², Karen Onel⁵, Jianmei Wang⁶, Kamal N. Bharucha⁷, Daniel J. Lovell², Alberto Martini⁸ and Nicolino Ruperto³, ¹IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ²PRCSG, Cincinnati, OH, ³PRINTO, Genoa, Italy, ⁴Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁵Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Genentech, South San Francisco, CA, ⁸Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: In the phase 3 TENDER trial of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA), decreases in neutrophil count were commonly observed.…
Abstract Number: 2677 • 2013 ACR/ARHP Annual Meeting
Disease Progression Into Adulthood In Patients With Juvenile Idiopathic Arthritis – a Longitudinal 30 Year Follow-Up Study
Anne Marit Selvaag, Hanne Aulie, Vibke Lilleby and Berit Flatø, Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: The aim of the study was to assess disease activity and health status in a previously studied cohort of patients with juvenile idiopathic arthritis…
Abstract Number: 274 • 2013 ACR/ARHP Annual Meeting
Reported Macrophage Activation Syndrome In Patients With Systemic-Onset Juvenile Idiopathic Arthritis Treated With Tocilizumab
Shumpei Yokota^1,2, Yasuhiko Itoh^2,3, Tomohiro Morio^2,4, Naokata Sumitomo^2,5 and Seiji Minota^2,6, ¹Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan, ²The Safety Evaluation Committee of Actemra® for JIA, Tokyo, Japan, ³pediatrics, Nippon Medical School, Tokyo, Japan, ⁴Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan, ⁵pediatrics, Nihon University School of Medicine, tokyo, Japan, ⁶Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (s-JIA) is a subtype of chronic childhood arthritis that is characterized by a spiking fever, rash, and arthritis. About 7%…
Abstract Number: 1164 • 2012 ACR/ARHP Annual Meeting
Orofacial Anomalies in Children with Confirmed Juvenile Idiopathic Arthritis
Bernd Koos¹, Franka Stahl de Castrillon², Robert Ciesielski¹ and Nikolay Tzaribachev³, ¹Clinic of Orthodontics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany, ²Department of Orthodontics, University of Rostock, Germany, Department of Orthodontics, University of Rostock, Germany, Rostock, Germany, ³Pediatric Rheumatology, Center for Rheumatic Diseases, Bad Bramstedt, Germany
Background/Purpose: In children with juvenile idiopathic arthritis (JIA) temporomandibular joints (TMJ) are affected in up to 96% of the patients, where TMJ arthritis is frequently…
Abstract Number: 2601 • 2012 ACR/ARHP Annual Meeting
Improving Delivery of Care for JIA Across a Multi-Center Network Using a Shared Data Registry and Quality Improvement Science: The Pediatric Rheumatology Care and Outcomes Improvement Network
Catherine A. Bingham¹, Lynn M. Darbie², Keith Marsolo³, Jennifer E. Weiss⁴, Stacy P. Ardoin⁵, Ronald Laxer⁶, D. J. Lovell⁷, Murray H. Passo⁸, Sheetal Vora⁹, Beth S. Gottlieb¹⁰, Timothy Beukelman¹¹, Nancy Griffin², Jason A. Stock¹², Michael L. Miller¹³, Karen Onel¹⁴, Tova Ronis¹⁵, Peter Margolis¹⁶ and Esi M. Morgan DeWitt¹⁷, ¹Pediatric Rheumatology, Penn State Hershey Children's Hospital, Hershey, PA, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH, ⁴Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, ⁵Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ⁶Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁷Cincinnati Children's Hospital, Cincinnati, OH, ⁸Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ⁹Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ¹⁰Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹²Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Rheumatology, Childrens Memorial Hospital, Chicago, IL, ¹⁴Pediatric Rheumatology, University of Chicago, Chicago, IL, ¹⁵Pediatric Rheumatology, Stanford University Hospital, Palo Alto, CA, ¹⁶Clinical Effectiveness, Cincinnati Children's Hospital, Cincinnati, OH, ¹⁷Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a quality improvement (QI) multi-center “learning network” that performs QI and research while tracking…
Abstract Number: 1173 • 2012 ACR/ARHP Annual Meeting
Targeting Remission in Juvenile Idiopathic Arthritis in Routine Clinical Care: Experience in 175 Newly-Diagnosed Patients
Alessandro Consolaro¹, Giorgia Negro¹, Nicoletta Solari¹, Cristina Ferrari¹, Sergio Davì¹, Silvia Pederzoli¹, Giulia Bracciolini¹, Maria C. Gallo¹, Alberto Martini² and Angelo Ravelli³, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The recent advances in the management of juvenile idiopathic arthritis (JIA) have increased considerably the potential to achieve disease remission or, at least, low…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].